DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
Semaglutide reduces kidney disease progression in T2D patients with CKD. FLOW trial (2024) supports broader use. Mounjaro shows similar signals.
The FLOW trial (NEJM 2024) showed semaglutide 1.0 mg reduced major kidney events (kidney failure, sustained eGFR drop, kidney death) by 24% in T2D + CKD patients over 3.5 years. Ozempic now carries a label update for kidney disease progression reduction.
Standard T2D + CKD prescribing applies. Nephrology co-management recommended for eGFR < 60. Ozempic is the most evidence-backed; Mounjaro Phase 3 kidney data is pending.
T2D + CKD coding strengthens PA approval significantly. Most commercial plans and Medicare approve readily.
Dehydration from GI side effects can transiently worsen kidney function. Hydrate aggressively (2-3 L daily). Avoid NSAIDs concurrently when possible.
For T2D patients with even mild CKD (eGFR 60-90), Ozempic should be a strong consideration. The kidney benefit is now on-label and clinically meaningful.
Yes. Switching from Ozempic (semaglutide) to Mounjaro (tirzepatide) is common and clinically supported for type 2 diabetes patients seeking better A1C reduction.
Yes, in moderation. Alcohol on Wegovy is not contraindicated, but most patients report dramatically reduced tolerance — 1-2 drinks may feel like 3-4.
Yes — and you should. Exercise on Wegovy preserves lean muscle mass, prevents the ~30% lean mass loss seen in patients who lose weight without strength training.
Semaglutide has a half-life of ~1 week. After your last dose, it takes ~5 weeks (5 half-lives) for the drug to fully clear your system.
No. Wegovy is contraindicated in pregnancy. Discontinue at least 2 months before attempting conception due to semaglutide's 1-week half-life.
Refrigerated 36-46°F before first use. After first use, can stay at room temperature (up to 86°F) для up to 28 days. Never freeze. Protect from light.
Editorial summary, not medical advice. Off-label and emerging uses should be discussed with a qualified clinician. Trial outcomes do not predict individual results.